v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities    
Net loss $ (173,774) $ (106,640)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 41,230 46,775
Impairment of goodwill and intangible assets 149,083 0
Non-cash gain from settlement of preexisting contractual relationship (3,858) 0
Loss on assets held for sale 9,491 92,706
Inventory write-downs and other non-cash items 1,301 3,866
Stock-based compensation 15,232 16,716
Amortization and accretion on marketable securities (1,088) (1,318)
Deferred income taxes (3,563) (20,385)
Loss on disposals of property, plant and equipment 14 759
Changes in operating assets and liabilities:    
Accounts receivable 4,073 38,799
Inventories (9,501) (9,998)
Accounts payable (655) (365)
Deferred revenue 1,986 7,156
Accrued warranty and retrofit costs 84 38
Accrued compensation and tax withholdings (3,816) 3,604
Accrued restructuring costs 26 (51)
Other assets and liabilities 9,540 (1,651)
Net cash provided by operating activities 35,805 70,011
Cash flows from investing activities    
Purchases of property, plant and equipment (20,234) (25,997)
Purchases of marketable securities (365,358) (312,990)
Sales and maturities of marketable securities 295,489 242,527
Acquisition of UK Biocentre, net of cash acquired (11,150) 0
Proceeds from other investment 0 2,130
Net investment hedge settlement 0 3,043
Deposit received for the sale of B Medical Systems business 28,000 0
Net cash used in investing activities (73,253) (91,287)
Cash flows from financing activities    
Proceeds from issuance of common stock 1,178 1,553
Payments of finance leases (583) (585)
Withholding tax payments on net share settlements on equity awards (2,521) 0
Excise tax payment for settled share repurchases 0 (11,376)
Share repurchases (50,046) 0
Net cash used in financing activities (51,972) (10,408)
Effects of exchange rate changes on cash, cash equivalents and restricted cash (2,594) 4,510
Net decrease in cash, cash equivalents and restricted cash (92,014) (27,174)
Cash, cash equivalents and restricted cash, beginning of period 296,685 320,990
Cash, cash equivalents and restricted cash, end of period 204,671 293,816
Supplemental disclosures:    
Cash paid for income taxes, net 7,017 2,243
Purchases of property, plant and equipment included in accounts payable and accrued expenses 6,978 4,652
Cash and cash equivalents of continuing operations 189,654  
Cash included in current assets held for sale 8,363  
Short-term restricted cash 2,414  
Long-term restricted cash included in other assets 4,240  
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 204,671 $ 293,816